Showing results (661-670 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|December 7, 2010
Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesJasmine Zain, Owen A O'ConnorInvestigational New Drugs|November 13, 2010
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primatesAeRang Kim, Cindy McCully, Rafael Cruz, et al.Investigational New Drugs|December 2, 2010
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell linesMiguel Muñoz, Ana González-Ortega, Rafael CoveñasInvestigational New Drugs|December 2, 2010
The DAC system and associations with multiple myelomaEnrique M Ocio, Jesús F San MiguelInvestigational New Drugs|October 22, 2010
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRPNienke A de Vries, Tessa Buckle, Jin Zhao, et al.Investigational New Drugs|November 4, 2010
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agentsMargaret E Macy, Deborah DeRyckere, Lia GoreInvestigational New Drugs|March 14, 2013
In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acidSidra Batool, Muhammad Sulaman Nawaz, Mohammad A KamalInvestigational New Drugs|February 12, 2013
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neckJean-Pascal Machiels, Marie-Christine Kaminsky, Ulrich Keller, et al.Investigational New Drugs|February 1, 1990
A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphomaH B Muss, N Spell, D Scudiery, et al.Investigational New Drugs|February 1, 1990
Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tractA S Goldenberg, D Kelsen, J Dougherty, et al.Pageof 372